EU Suspends Deadline For Illumina's $8B Grail Deal
European enforcers hit the pause button on their review of DNA sequencing giant Illumina's $8 billion reacquisition of cancer detection outfit Grail, a deal already being challenged by the Federal Trade...To view the full article, register now.
Already a subscriber? Click here to view full article